World

Sprouts Farmers Market Adds Else Kids Nutrition Products to its Retail Stores Across the U.S.

Retrieved on: 
Monday, January 17, 2022 - 12:00pm
Sprouts, Sprout, Chocolate, Harvard Medical School, Kid, Infant, Nutrient, Pediatrics, Society, Growth, CEO, GLOBE, World, Boston Children's Hospital, Schneider Children's Medical Center of Israel, Medical Center, Instagram, Toddler nutrition, BABY, Health, Facebook, Parent, Company, Hospital, Toddler, Rambam Health Care Campus, TSX Venture Exchange, Communication, Farmer, Sprouts Farmers Market, Animal, Tel Aviv University, Amazon

In the 10 months of sales since the February 2021 launch of Else Toddler Nutrition product at Sprouts Farmers Market, sales velocity grew steadily to 1.2 UPSPW (units per store per week), surpassing the category average.

Key Points: 
  • In the 10 months of sales since the February 2021 launch of Else Toddler Nutrition product at Sprouts Farmers Market, sales velocity grew steadily to 1.2 UPSPW (units per store per week), surpassing the category average.
  • We believe that the addition of the new Kids products will accelerate overall sales growth at Sprouts.
  • Were excited that consumers with children shopping at Sprouts will enjoy the same Clean Label Purity Award-Winning quality, and whole Plant-Based Nutrition that our Toddler Nutrition products have been providing to thousands of toddlers nationwide.
  • Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults.

Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

Retrieved on: 
Monday, January 17, 2022 - 12:00pm
Amlodipine, III, Indapamide, Patient, Research, Imperial College Healthcare NHS Trust, Academic clinical trial, George Institute for Global Health, Clinical trial, Pharmacology, International Society, Infarction, COVID-19, Guideline, Vascular dementia, Medical school, Safety, Death, Faculty, CEO, Stroke, World, School, NHS, Public health, Industry, Blood pressure, Imperial College Faculty of Medicine, Loma Linda University School of Public Health, Department of Nutrition, Cardiovascular disease, Type 2 diabetes, Heart, WHO, Medicine, Telmisartan, GP, International Society on Hypertension in Blacks, World Health Organization, Global Health, ICTU, Imperial College London, Hospital, Degenerative disease, Pharmaceutical industry, Hypertension

The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.

Key Points: 
  • The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.
  • Professor Ray leads a team of highly experienced operational staff to deliverexcellence in clinical trial management.
  • We are delighted to collaborate with Imperial Clinical Trials Unit to expand our research into the UK, where high blood pressure remains a significant silent killer and many patients are still uncontrolled.
  • A therapy that can more effectively control a patients blood pressure and reduce the significant pill burden that can lead patients to discontinue therapy could help transform how we treat high blood pressure.

Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B

Retrieved on: 
Monday, January 17, 2022 - 10:08am
Research, Gannex, Liver cancer, HKEX, Cornerstone, Acne, CHB, Investigational New Drug, Prevalence, PD-1, RNA, COVID-19, GBM, Safety, Hong Kong Stock Exchange, NASH, Hepatitis B, Nas, CDC classification system for HIV infection, Hepatitis C, WHO, OBI Pharma, Inc., FXR, Doctor of Philosophy, HBsAg, Food, World Health Organization, Phase, Interim, FDA, Patient, Institute of Liver and Biliary Sciences, World, Association, HBV, IIB, DHHS, American Association, Pegasys, R, American Association for Cancer Research, AASLD, RNA polymerase II, CEO, Degenerative disease, IND, Hepatitis B virus, HIV/AIDS, FASN, PBC, Food and Drug Administration, PD-L1, THR, United States Department of Health and Human Services, Vaccine, Pharmaceutical industry, Medical device, Cancer

HANGZHOU and SHAOXING, China, Jan. 17, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today the Investigational New Drug (IND) application approval by U.S. Food and Drug Administration (FDA) and initiation of global development of ASC22 (Envafolimab), a first-in-class, subcutaneously administered PD-L1 antibody for functional cure of chronic hepatitis B (CHB).

Key Points: 
  • Such inclusion is a singular honor and indicates the high level with which the AASLD review committee regards Ascletis' research in CHB functional cure.
  • "ASC22 (Envafolimab) U.S. IND approval enables us to initiate U.S. and global clinical trials for CHB functional cure.
  • Viral Diseases: (1) Hepatitis B Virus (functional cure): focus on breakthrough therapies for CHB functional cure with a subcutaneously-injected PD-L1 antibody ASC22 and Pegasys as cornerstone drugs.
  • (3) HIV/AIDS: ASC22, an immune therapy to restore HIV-specific immune responses and eventually lead to a functional cure of HIV-infected patients.

Global Air Ambulance Services Market (2021 to 2027) - Featuring Acadian Ambulance Services, Air Methods and Falck Holding Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 9:30am
Hospitals, Air, Health, Transport, Transfer, CAGR, Patient, Research, MERS, COVID-19, Ambulance, Travel, Adoption, SARS, Death, Government, World, Pandemic, Accident, Joint Medical Service (Germany), World Health Organization, Infection, REVA, Hospital, Transport, Airline, Marketing, H1N1

The global air ambulance services market is anticipated to grow at a substantial CAGR of 12.2% during the forecast period.

Key Points: 
  • The global air ambulance services market is anticipated to grow at a substantial CAGR of 12.2% during the forecast period.
  • Such pandemics will give a significant boom to the global air ambulance services market.
  • The major companies serving the global air ambulance services market include Acadian Ambulance Services, Inc., Air Methods Corp., Falck Holding A/S, IAS Medical, Ltd., PHI Group, Inc., REVA, Inc., and others.
  • Insights about market determinants that are stimulating the global air ambulance services market.

Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B

Retrieved on: 
Monday, January 17, 2022 - 9:53am
Research, Gannex, Liver cancer, HKEX, Cornerstone, Acne, CHB, Investigational New Drug, Prevalence, PD-1, RNA, COVID-19, GBM, Safety, Hong Kong Stock Exchange, NASH, Nas, WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents, Hepatitis C, WHO, OBI Pharma, Inc., FXR, Doctor of Philosophy, HBsAg, Food, World Health Organization, Interim, FDA, Patient, Institute of Liver and Biliary Sciences, World, Association, HBV, IIB, DHHS, American Association, Pegasys, R, American Association for Cancer Research, AASLD, RNA polymerase II, CEO, Degenerative disease, IND, Hepatitis B virus, HIV/AIDS, FASN, PBC, Food and Drug Administration, PD-L1, THR, United States Department of Health and Human Services, Pharmaceutical industry, Vaccine, Medical device, Cancer

Such inclusion is a singular honor and indicates the high level with which the AASLD review committee regards Ascletis' research in CHB functional cure.

Key Points: 
  • Such inclusion is a singular honor and indicates the high level with which the AASLD review committee regards Ascletis' research in CHB functional cure.
  • "ASC22 (Envafolimab) U.S. IND approval enables us to initiate U.S. and global clinical trials for CHB functional cure.
  • Viral Diseases: (1) Hepatitis B Virus (functional cure): focus on breakthrough therapies for CHB functional cure with a subcutaneously-injected PD-L1 antibody ASC22 and Pegasys as cornerstone drugs.
  • (3) HIV/AIDS: ASC22, an immune therapy to restore HIV-specific immune responses and eventually lead to a functional cure of HIV-infected patients.

Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

Retrieved on: 
Monday, January 17, 2022 - 7:00am
Amlodipine, III, Indapamide, Patient, Research, Imperial College Healthcare NHS Trust, Academic clinical trial, George Institute for Global Health, Clinical trial, Pharmacology, International Society, Infarction, COVID-19, Guideline, Vascular dementia, Medical school, Safety, Death, Faculty, CEO, Stroke, World, School, NHS, Public health, Industry, Blood pressure, Imperial College Faculty of Medicine, Loma Linda University School of Public Health, Department of Nutrition, Cardiovascular disease, Type 2 diabetes, Heart, WHO, Medicine, Telmisartan, GP, International Society on Hypertension in Blacks, World Health Organization, Global Health, ICTU, Imperial College London, Hospital, Degenerative disease, Pharmaceutical industry, Hypertension

The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.

Key Points: 
  • The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.
  • Professor Ray leads a team of highly experienced operational staff to deliverexcellence in clinical trial management.
  • We are delighted to collaborate with Imperial Clinical Trials Unit to expand our research into the UK, where high blood pressure remains a significant silent killer and many patients are still uncontrolled.
  • A therapy that can more effectively control a patients blood pressure and reduce the significant pill burden that can lead patients to discontinue therapy could help transform how we treat high blood pressure.

10 richest men double their fortunes in pandemic while incomes of 99 per cent of humanity fall

Retrieved on: 
Monday, January 17, 2022 - 12:30am
Income, Woman, World, Inequality, Colonialism, Stockholm Environment Institute, Research, Institute, Paris, Man, Vaccine, Carbon, Poverty, Bernard Arnault, African Americans, COVID-19, CRB, Parity, Death, WEF, IMF, Violence, Oxfam, School-related gender-based violence, Zoltan Sarosy, Hunger, Billionaire, Government, Female, White, Home Office hostile environment policy, Tax, Office for National Statistics, SEI, CERB, Heart, Life expectancy, Wildfire, Tornado, Statistics, Fallout 4 downloadable content, Climate change, GDP, OECD, World Economic Forum, Claw, Flood, List of national and international statistical services, World Bank, Policy, Renewable energy, Agriculture, Animal, Pharmaceutical industry, Drug, Creative industries, Restaurant, Forbes

Billionaires' wealth has risen more in the 22 months since COVID-19 began than it has in the last 14 years.

Key Points: 
  • Billionaires' wealth has risen more in the 22 months since COVID-19 began than it has in the last 14 years.
  • All this, while still leaving these men $10 billionbetter off than they were before the pandemic.
  • The world's response to the pandemic has unleashed this economic violence particularly acutely across racialized, marginalized and gendered lines.
  • The 252 richest men have more wealth than all one billion women and girls in Africa, Latin America and the Caribbean combined.

Sun Nuclear Announces 2022 QA & Dosimetry Symposium (QADS) Program

Retrieved on: 
Friday, January 14, 2022 - 9:30pm
Securities Exchange Act of 1934, Technology, Continuing education, Quality, AAPM, Conversation, Yellow Sun (nuclear weapon), Publication, Financial condition report, Hope, COVID-19, Medical error, Adoption, Radiation therapy, NYSE, Patient safety, Safety, Risk, Learning, SAM, World, Incident, Diagnosis, Quality assurance, U.S. Securities and Exchange Commission, Time, Industry, Duke University, Quality management, Program, Analysis, Medical physicist, Physics, Result, Bonnet Creek Resort, Cancer, World Health Organization, MDCB, Security (finance), Medical imaging, MIR, COVID, Medical device, Solution

MELBOURNE, Fla., Jan. 14, 2022 /PRNewswire/ -- Sun Nuclear Corporation (Sun Nuclear), a wholly-owned subsidiary of Mirion Technologies, Inc. (NYSE: MIR) ("Mirion"), today announced the full program for the 2022 QA & Dosimetry Symposium (QADS), April 8-9, in Orlando, Florida.

Key Points: 
  • MELBOURNE, Fla., Jan. 14, 2022 /PRNewswire/ -- Sun Nuclear Corporation (Sun Nuclear), a wholly-owned subsidiary of Mirion Technologies, Inc. (NYSE: MIR) ("Mirion"), today announced the full program for the 2022 QA & Dosimetry Symposium (QADS), April 8-9, in Orlando, Florida.
  • Hosted by Sun Nuclear, QADS is the premier Continuing Education event focused exclusively on Quality and Patient Safety in Radiation Oncology.
  • "We're pleased to share the 2022 program, featuring multidisciplinary talks with practical guidance on Quality Assurance."
  • Sun Nuclear is also pleased to welcome Ehsan Samei, Ph.D., to its QADS program.

DEWALT® To Premiere New Innovation for the Commercial Concrete and Masonry Construction Industries at World of Concrete® Trade Show

Retrieved on: 
Friday, January 14, 2022 - 7:39pm
Carbon, Diamond, Technology, Buy American Act, SDS, Stanley Black & Decker, CCU, XR, LinkedIn, MAX, SWK, Dust, NYSE, OSHA, Construction, Workload, Solution, Vibration, Cordless, Instagram, Electronics, Concrete, Industry, Company, World, Twitter, Intention, USDA, World of Concrete, Private investigator, Electric motor, Printed circuit board, Abrasive, Electric battery, Facebook

Attendees at the World of Concrete Trade Show will be among some of the first to test and demo these new products onsite:

Key Points: 
  • Attendees at the World of Concrete Trade Show will be among some of the first to test and demo these new products onsite:
    60V MAX* Cordless SDS MAX Chipping Hammers in 22 lb.
  • (DCH832X1) models
    Designed for heavy-duty demolition, concrete, and masonry work, the DEWALT 60V MAX* 22 lb.
  • Cordless SDS MAX Chipping Hammer quickly breaks down dense concrete with up to 19.4 Joules of impact energy**.
  • When critical mechanical anchor connections are required, DEWALT heavy-duty Critical Connection Undercut (CCU+) Anchors get the job done.

World Insurance Associates Acquires Rhode Island Based Broker Team

Retrieved on: 
Friday, January 14, 2022 - 3:31pm
Entrepreneurship, Insurance, Retirement, WIA, Insurance broker, CEO, GLOBE, World, Solution, Broker, Business, LLC, Financial services, Boilermaker

Tinton Falls, NJ, Jan. 14, 2022 (GLOBE NEWSWIRE) -- World Insurance Associates LLC (WIA), a Top 100 Insurance Brokerage, announced today that it acquired a team of five Rhode Island based brokers, led by David White on December 31, 2021.

Key Points: 
  • Tinton Falls, NJ, Jan. 14, 2022 (GLOBE NEWSWIRE) -- World Insurance Associates LLC (WIA), a Top 100 Insurance Brokerage, announced today that it acquired a team of five Rhode Island based brokers, led by David White on December 31, 2021.
  • We are happy to welcome David White and his team to the World family, says Rich Eknoian, CEO and Co-Founder of WIA.
  • David's team and support staff have a wealth of experience in the community and are committed to offering insurance solutions that meet their clients needs.
  • World Insurance Associates LLC (World) is headquartered in Tinton Falls, N.J., and is a full-service insurance organization providing individuals and businesses with top products and services across personal and commercial insurance lines, employee benefits, retirement and financial services and human capital management solutions.